Air purification manufacturer Fellowes’ AeraMax Pro range have shown a 99.99 per cent airborne reduction of a coronavirus surrogate within 60 minutes of operation
Certified by Shanghai WEIPU Chemical Technology Service Company, Fellowes AeraMax Pro air purifiers demonstrated effectiveness in reducing the aerosolised airborne concentration of human coronavirus 229E in a test chamber.
As it is not yet possible, or ethically responsible to aerosolise Sars-CoV-2 for airborne testing in the current climate, the coronavirus 229E was used as a surrogate to Sars-CoV-2.
Furthermore, AeraMax Pro air purifiers have also been proven to remove 99.9 per cent of the H1N1 virus within 35 minutes of operation, as certified by Airmid Health Group in Dublin, Ireland.
Dr. Rajiv Sahay, director of Environmental Diagnostics Laboratory at Florida-based Pure Air Control Services added: “These latest test results on the Fellowes AeraMax Pro air purifiers provided by an independent third-party accredited (ISO/IEC 17025) laboratory are significant.
“I continue to be impressed with the findings on the efficacy of this technology/device by Fellowes. Typically, single-strand RNA envelope viruses (e.g. common cold coronavirus 229E, etc.) are used as a surrogate for SARS-CoV-2 to study the antiviral effect of a specific device.”
AeraMax Pro purifiers combine four-stage True HEPA filtration with EnviroSmart and PureView technologies.
EnviroSmart utilises multiple sensors to monitor contaminants and room occupancy continuously and adjusts automatically to provide maximum protection – on demand.
PureView makes the invisible, visible with real-time screen updates on air quality and machine performance.
“I’m delighted that the results of these tests offer the reassurance that Fellowes AeraMax Pro air purifiers are indeed effective in removing forms of coronavirus from indoor air,” said Fellowes Brands UK and Ireland head Darryl Brunt.
